Prevention of catheter-related bloodstream infections: An appraisal of developments in designing an infection-resistant 'dream dialysis-catheter'

Nephrology

Volumn 10, Issue 3, 2005, Pages 240-248

  Saxena, Anil K ^a   Panhotra, Bodh R ^b  

^a KING FAHAD HOSPITAL   (Saudi Arabia)

^b NONE

Author keywords

Blood stream infections; Catheters; Haemodialysis; Preventive strategies

Indexed keywords

BACTERIAL COLONIZATION; CATHETER; CATHETER INFECTION; CENTRAL VENOUS CATHETER; DIABETES MELLITUS; DIALYSIS CATHETER; ELDERLY CARE; HEMODIALYSIS; HUMAN; IMMUNOPATHOLOGY; INFECTION RESISTANCE; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; RELIABILITY; REVIEW; THROMBOSIS; VASCULAR ACCESS;

BACTEREMIA; BLOOD-BORNE PATHOGENS; CATHETERIZATION; EQUIPMENT DESIGN; HUMANS; INFECTION CONTROL; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 21344471162     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00382.x     Document Type: Review

References (87)

1. Schwab SJ, Beathard G. The haemodialysis catheter conundrum: Hate living with them, but can't live without them. Kidney Int. 1999; 56: 1-17.
2. Galli F. Central venous catheter in haemodialysis: The light and shade of a still necessary evil. J. Vasc. Access 2000; 1: 125-8.
3. Butterly DW, Schwab SJ. Dialysis access infections. Curr. Opin. Nephrol. Hypertens. 2000; 9: 631-5.
4. Kairaitis LK, Gottlieb T. Outcome and complications of temporary haemodialysis catheters. Nephrol. Dial. Transplant. 1999; 14: 1710-M.
5. Oliver MJ, Gallery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteraemia from temporary haemodialysis catheters by site of insertion and duration of use: A prospective study. Kidney Int. 2000; 58: 2543-5.
6. Saad TF. Bacteraemia associated with tunnelled, cuffed haemodialysis catheters. Am. J. Kidney Dis. 1999; 34: 1114-24.
7. Ashwani RS, Mercia RS, Kenneth EC, Richard C, Jeanette AC. Use of standardarized ratios to examine viability in haemodialysis vascular access across facilities. Am. J. Kidney Dis. 2000; 35: 275-81.
8. Jaar BG, Herman JA, Furth SL, Briggs W, Powe NR. Septicaemia in diabetic haemodialysis patients: Comparison of incidence, risk factors and mortality with non-diabetic patients. Am. J. Kidney Dis. 2000; 35: 282-92.
9. Munshi SK, Narayanaswami VK, Nicholas AT, Harneeta B, Nelson TC, Graham W. Outcome of renal replacement therapy in the very elderly. Nephrol. Dial. Transplant. 2001; 16: 128-33.
10. Saxena AK, Panhotra BR, Chopra R. Advancing age and risk of nasal carriage of Staphylococcus aureus among patients on long-term hospital-based haemodialysis. Ann. Saudi Med. 2005; 24: 337-42.
11. Saxena AK, Panhotra BR, Venkateshappa CK, Wahid U. The role of Staphylococcus aureus nasal carriage and the type of vascular access in the outcome of high-risk patients on haemodialysis. J. Vasc. Access 2002; 3: 74-9.
12. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteraemia. N. Engl. J. Med. 2001; 344: 11-16.
13. Saxena AK, Panhotra BR, Wahid U. The impact of nasal carriage of Staphylococcus aureus on the type of vascular access and dialysis access-related septicaemia in elderly. Dial. Transplant. 2003; 32: 2-10.
14. Patti JM, Allen BL, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu. Rev. Microbiol. 1994; 48: 585-617.
15. Robinson DL, Fowler WG, Saxton DJ et al. Bacterial endocarditis in haemodialysis patients. Am. J. Kidney Dis. 1997; 30: 521-4.
16. Kovalik EC, Raymond JR, Albers FJ et al. A clustering of epidural abscesses in chronic haemodialysis patients: Risks of salvaging access catheters in case of infection. J. Am. Soc. Nephrol. 1996; 7: 2264-7.
17. Chang CF, Kuo BIT, Chen TL, Yang WC, Lee SD, Lin CC. Infective endocarditis in maintenance haemodialysis patients: Fifteen years' experience in one medical center. J. Nephrol. 2004; 17: 228-35.
18. Marr KA, Kong LK, Fowler VG et al. Incidence and outcome of Staphylococcus aureus bacteraemia in haemodialysis patients. Kidney Int. 1998; 54: 1684-9.
19. Foster TJ, McDevitt D. Surface-associated proteins of Staphylococcus aureus: Their possible roles in virulence. FEMS Microbiol. 1994; 118: 199-205.
20. Saxena AK, Panhotra BR, Naguib M et al. Septicaemia in haemodialysis: A focus on bacterial flora and antibiotic access salvage. Saudi J. Kidney Dis. Transplant. 2002; 13: 29-34.
21. Cheesbrough JS, Finch RG, Burden RP. A prospective study of mechanisms of infection associated with haemodialysis catheters. J. Infect. Dis. 1986; 154: 579-89.
22. De Cicco M, Campisi C, Matovic M. Central venous catheter-related bloodstream infections: Pathogenesis factors, new perspectives in prevention and early diagnosis. J. Vasc. Access 2003; 4: 83-91.
23. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections. Am. J. Infect. Control 1988; 16: 128-40.
24. Raad II, Hohn DC, Gilbreth BJ et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect. Control Hosp. Epidemiol. 1994; 15: 231-8.
25. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone - iodine, alcohol and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991; 338: 339-43.
26. Levin A, Mason AJ, Jindal KK, Fong IW, Goldstein MB. Prevention of haemodialysis subclavian vein catheter infections by topical povidone-iodine. Kidney Int. 1991; 40: 934-48.
27. Maki DG, Band JD. Comparative study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. Am. J. Med. 1981; 70: 739-44.
28. Maki DG, Mermel L. Meta-analysis of transparent versus gauze dressing for central venous catheter use. Infect. Control Hosp. Epidemiol. 1997; 18 (Suppl.): 51-6.
29. Silverberg D, Stozenko F, Blum M et al. Mupirocin ointment application at exit site of temporary central line haemodialysis catheters markedly reduces S. aureus bloodstream infections. Dial. Transplant. 2003; 32: 484-9.
30. Johnson DW, MacGinley R, Kay TD et al. A randomised controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol. Dial. Transplant. 2002; 17: 1802-7.
31. Rao SP, Oreopoulos DG. Unusual complications of polyurethane PD catheter. Perit. Dial Int. 1997; 17: 410-12.
32. Riu S, Ruiz CG, Martinez-Vera A, Peralta C, Oliver JA. Spontaneous rupture of polyurethane peritoneal catheter: A possible deleterious effect of mupirocin ointment. Nephrol. Dial. Transplant. 1998; 13: 1870-71.
33. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors of bacteraemia in chronic haemodialysis patients. J. Am. Soc. Nephrol. 1998; 9: 869-87.
34. Goetz AM, Wagener MM, Miller JM, Muder RR. Risk of infection due to central venous catheter: Effect of site of placement and catheter type. Infect. Control Hosp. Epidemiol. 1998; 19: 842-5.
35. Viale P, Politi E, Sisti M, Confalonieri M, Alberici F. Impact of central venous catheters (CVC) management on infectious risk. J. Hosp. Infect. 1998; 40 (Suppl. A): 8.1.8.
36. Trotuer SJ, Verimakis C, O'Brian J, Auer AI. Femoral deep vein thrombosis associated with central venous catheterisation: Results from prospective randomised trial. Crit. Care Med. 1995; 23: 52-9.
37. Boelaert JR, Van Landuyt HW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemia in haemodialysis patients. Nephrol. Dial. Transplant. 1993; 8: 235-39.
38. Kluytmans JA, Manders MJ, Van Bommel E, Verbrugh H. Elimination of nasal carriage of Staphylococcus aureus in haemodialysis patients. Infect. Control Hosp. Epidemiol. 1996; 17: 793-7.
39. McAnally TP, Lewis MR, Brown DR. Effect of rifampicin and bacitracin on nasal carriers of Staphylococcus aureus. Antimicrob. Agents Chemother. 1984; 25: 422-6.
40. Watanabe H, Masaki H, Asoh N, Watanabe K, Oishi K, Furumoto A. Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan. J. Hosp. Infect. 2001; 47: 294-300.
41. Shineneld H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving haemodialysis. N. Eng. J. Med. 2002; 346: 491-6.
42. Pisoni RL, Young EW, Dykstra DM et al. Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int. 2002; 61: 305-16.
43. Sands J, Miranda CL. Increasing numbers of AV fistulas for haemodialysis access. Clin. Nephrol. 1997; 48: 114-17.
44. Konner K. Increasing the proportion of diabetics with AV fistulas. Semin. Dial. 2001; 14: 1-4.
45. Saxena AK, Panhotra BR, Naguib M et al. The impact of achieving goal for AV fistula set by NKF-DOQI, on Staphylococcus aureus septicaemia. Dial. Transplant. 2002; 31: 16-23.
46. Saxena AK, Panhotra BR, Naguib M et al. Outcome of dialysis access-related septicaemia among diabetics following optimised AV-fistula placement. Kidney Blood Press. Res. 2002; 25: 109-14.
47. Oliver MJ, Rothwell DM, Fung K, Hux JE, Lok CE. Late creation of vascular access for haemodialysis and increased risk of sepsis. J. Am. Soc. Nephrol. 2004; 15: 1936-42.
48. Schwab SJ. Improving access patency: Pre-end-stage renal disease strategies. J. Am. Soc. Nephrol. 1998; 9: 124-9.
49. Ravani P, Marinangeli G, Stacchiotti L, Malberti F. Structured pre-dialysis programs: More than just timely referral? J. Nephrol. 2003; 16: 862-9.
50. Sherertz RJ, Ely EW, Westbrook DM et al. Education of physicians-in-training can reduce the risk of vascular catheter infection. Ann. Intern. Med. 2000; 132: 641-8.
51. Eggimann P, Harberth S, Constantin MN et al. Impact of prevention strategy targeted at vascular-access care in incidence of infections acquired in intensive care unit. Lancet 2000; 355: 1864-8.
52. Kretzer EK, Larson EL. Behavioural interventions to improve infection control practices. Am. J. Infect. Control 1998; 26: 245-53.
53. Elliott TSJ, Tebbs SE. Prevention of central venous catheter-related infections. J. Hosp. Infect. 1998; 40: 193-201.
54. Maki DG, Stoltz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: A randomised, controlled study. Ann. Intern. Med. 1997; 127: 157-66.
55. Ciresi D, Albrecht RM, Volkers PA, Scholten DJ. Failure of an antiseptic bonding to prevent central venous catheter-related infection and sepsis. Am. Surg. 1996; 62: 641-6.
56. Pemberton LB, Ross V, Cuddy P et al. No difference in catheter sepsis between standard and antiseptic central venous catheters: A prospective randomised trial. Arch. Surg. 1996; 131: 986-9.
57. Heard SO, Wagle M, Vijayakumar K et al. The influence of nipple lumen central venous catheters coated with chlorhexidine and silver sulphadiazine on the incidence of catheter-related bacteraemia. Arch. Intern. Med. 1998; 158: 81-7.
58. Oda T, Junichiro H, Noami K, Mikami K. Anaphylactic shock induced by an antiseptic-coated venous catheter. Anaesthesiology 1997; 87: 1242-4.
59. World Health Organization. Central Venous Catheters (Arrow-guard) Recalled: Anaphylactic Shock. Geneva: World Health Organization, 1997.
60. Raad I, Darouiche R, Hachem R et al. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampicin. J. Infect. Dis. 1996; 173: 418-24.
61. Raad I, Darouiche R, Hachem R et al. Antibiotics and prevention of microbial colonization of catheters. Antimicrob. Agents Chemother. 1995; 39: 2397-400.
62. Darouich RO, Raad II, Heard SO et al. A comparison of two anti-microbial - impregnated central venous catheters. N. Eng. J. Med. 1999; 340: 1-8.
63. Raad I, Darouiche R, Hachem R et al. Antimicrobial durability and rare ultrastructural colonization of indwelling central venous catheters coated with minocycline and rifampicin. Crit. Care Med. 1998; 26: 219-24.
64. Bambauer R, Latza R, Bambauer S, Tobin E. Large bore catheters with surface treatments versus untreated catheters for vascular access in haemodialysis. Artif. Organs 2004; 28: 604-10.
65. Bleyer A, Mason L, Raad I, Sherertz R. A Randomised Double Blind Trial Comparing Minocycline/EDTA with Heparin As Flush Solutions for Haemodialysis Catheters. Program and abstracts of 4th Decennial Conference Program Committee, March 5-9, 2000. Atlanta, GA: Unknown Publisher. Abstract P-S 1-31.
66. Carratala J, Niubo J, Fernandez-Sevilla A et al. Randomised, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheter-related infection in neutropenic patients with cancer. Antimicrob. Agents Chemother. 1999; 43: 2200-4.
67. Dogra GK, Herson H, Hutchison B et al. Prevention of tunnelled haemodialysis catheter-related infections using catheter-restricted filling of gentamicin and citrate: A randomised control study. J. Am. Soc. Nephrol. 2002; 13: 2133-9.
68. Pervez A, Ahmad M, Ram S et al. Antibiotic lock technique for prevention of cuffed tunnel catheter associated with bacteraemia. J. Vasc. Access 2002; 3: 108-13.
69. FDA Issues Warning on Tricitrasol Dialysis Catheter Anticoagulant [Internet]. FDA Talk Paper. Rockville, MD: Food and Drug Administration, US Department of Health and Human Services, Public Health Service. Retrieved on 14 April 2000, from: http:// www.fda.gov/bbs/topics/ANSWERS/ANS01009.html
70. McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunnelled haemodialysis catheters with gentamicin and heparin. Kidney Int. 2004; 66: 801-5.
71. Saxena AK, Panhotra BR, Naguib M. Sudden irreversible sensory - neutal hearing loss in a diabetic on haemodialysis, receiving amikacin as antibiotic-heparin lock. Pharmacotherapy 2002; 22: 105-8.
72. Saxena AK. Ototoxicity from the aminoglycosides-hepatin/citrate locks applied for the prevention for the prevention of haemodialysis catheter-related infections. J. Vasc. Access 2003; 4: 35-6.
73. Saxena AK, Panhotra BR, Al-Ghamdi AMA. Antibiotic-heparin lock technique: A potentially precious tool to prevent haemodialysis catheter-related septicaemia. Saudi J. Kidney Dis. Transplant. 2004; 15: 67-70.
74. Francisco IL, Mercedes P, Pedro O, Rafel S, Enrique C. Cefotaxime, twenty years later; observational study in critically ill patients. Enferm. Infecc. Microbiol. Clin. 2001; 19: 211-18.
75. Moore HL, Twarclowski ZJ. The air-bubble method of locking central vein catheters with acidified concentrated sodium chloride as a bactericidal agent: In-vitro studies. Hemodial. Int. 2003; 7: 311-19.
76. Twardowski ZJ, Reams G, Prowant BF, Moore HL, Van Stone JC. Air-bubble method of locking central-vein catheters for prevention of hub colonization: A pilot study. Hemodial. Int. 2003; 7: 320-25.
77. Appelgren P, Ransjo U, Bindslev L, Esperson F, Larm O. Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo; Results from a prospective randomised trial. Crit. Care Med. 1996; 24: 1482-9.
78. Liu WK, Tebbs SE, Byrne PO, Elliot TS. Effects of electric current on bacteria colonizing intravenous catheter. J. Infect. 1993; 27: 261-9.
79. Raad I, Hachem R, Zermano A, Stephens LC, Bodey GP. Silver iontophotetic catheter: A prototype of a long-term anti-infective vascular access device. J. Infect. Dis. 1996; 173: 495-8.
80. Vaudaux P, Pittet D, Haeberli A et al. Fibronectin is more active than fibrin or fibrinogen in promoting Staphylococcus aureus adherence to inserted intravascular catheters. J. Infect. Dis. 1993; 167: 633-41.
81. Huesca M, Sun Q, Peralta R, Sauder DN, McGavin MJ. Synthetic peptide immunogens elicit polyclonal and monoclonal antibodies specific for linear epitopes in the D motifs of Staphylococcus aureus fibtonectin-binding protein, which are composed of ammo acids that are essential for fibronectin binding. Infect. Immun. 2000; 68: 1156-63.
82. Sun Q, Smith GM, Zahradka C, McGavin MJ. Identification of D motif epitopes in Staphylococcus aureus fibronectin-binding protein for the production of antibody inhibitors of fibronectin binding. Infect. Immun. 1997; 65: 537-43.
83. Davies DG, Parsec MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998; 280: 295-8.
84. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998; 280: 295-8.
85. Parsek MR, Val DL, Hanzelka BL, Cronan Jr JE, Greenberg EP. Acyl homoserine-lactone quorum-sensing signal generation. Proc. Natl Acad. Sci. USA 1999; 96: 4360-65.
86. Otto M, Sussmuth R, Vuong C, Jung G, Gotz F. Inhibition of virulence factor expression in Staphylococcus aureus by the Staphylococcus epidermidis agr pheromone and derivative. FEBS Lett. 1999; 450: 257-62.
87. Ziebuhr W, Heilmann C, Gotz F et al. Detection of the intercellular gene cluster (ica) and phase variation in S. epidermidis blood culture strains and mucosal isolates. Infect. Immun. 1997; 65: 890-96.